Biofourmis is a leading health technology company that delivers personalized, predictive care through AI-powered remote patient monitoring and digital therapeutics. The platform leverages real-time data from wearable devices and clinical-grade sensors to detect early signs of deterioration, optimize therapy, and enable hospital-level care at home.
Headquartered in Boston, Biofourmis is redefining how healthcare is delivered by moving care from hospital settings to the home, making it more continuous, connected, and proactive. Its FDA-cleared solutions support providers, payers, and biopharmaceutical companies in improving patient outcomes, reducing readmissions, and lowering healthcare costs.
Biofourmis combines artificial intelligence, advanced biosensors, and a robust analytics engine to create a personalized picture of each patient’s health status. It enables timely interventions based on data-driven insights, making it a scalable solution for value-based and remote care models.
Features
Remote Patient Monitoring: Biofourmis continuously tracks patients’ vital signs using wearable biosensors, enabling clinicians to monitor conditions like heart failure, hypertension, and COVID-19 remotely.
FDA-Cleared Digital Therapeutics: The platform offers digital therapies designed to manage chronic conditions, improve treatment adherence, and personalize therapy recommendations.
Predictive Analytics: Using machine learning, Biofourmis analyzes physiologic data to identify early signs of health deterioration up to several days in advance.
Personalized Care Pathways: Each patient’s care plan is customized based on real-time data, comorbidities, and clinical guidelines, ensuring targeted interventions.
Hospital-at-Home Support: Biofourmis enables acute-level care at home, including post-discharge management and virtual rounds by care teams.
Clinician Dashboard: Care teams have access to a centralized portal with patient data, alerts, trend analysis, and risk stratification tools.
Patient Engagement App: Patients use a mobile app to receive reminders, report symptoms, and communicate with care teams, enhancing adherence and engagement.
EHR Integration: The platform integrates with electronic health records, ensuring seamless workflow compatibility and data interoperability.
Regulatory Compliance: Biofourmis is HIPAA-compliant and operates in alignment with global data security and privacy regulations.
How It Works
Biofourmis begins by enrolling patients into a specific care program—such as heart failure, post-surgical recovery, or oncology care. Each patient is provided with a wearable biosensor, typically worn on the upper arm, which continuously collects physiologic data such as heart rate, respiratory rate, temperature, and activity.
The data is transmitted in real time to Biofourmis’ cloud-based platform, where AI algorithms analyze patterns and deviations from the patient’s baseline. The system generates actionable insights and predictive alerts for clinicians, often detecting signs of deterioration before symptoms become severe.
Patients also interact with the platform via a mobile app to input symptoms, receive medication reminders, and communicate with their care team. Clinicians monitor patient data through a dashboard that highlights trends, clinical alerts, and risk levels, helping prioritize care delivery and interventions.
This end-to-end monitoring system supports home-based care models while maintaining clinical rigor, improving care access, and enabling proactive interventions that reduce hospitalizations.
Use Cases
Hospitals use Biofourmis to extend their care continuum into patients’ homes, particularly for post-discharge monitoring and chronic disease management.
Health systems implement the platform for hospital-at-home programs, providing acute-level care to patients outside of inpatient settings.
Cardiology clinics rely on Biofourmis to monitor heart failure and atrial fibrillation patients remotely, helping reduce readmissions and improve medication adherence.
Biopharma companies partner with Biofourmis for clinical trials, using the platform to collect continuous real-world data and monitor treatment outcomes remotely.
Payers use Biofourmis to support value-based care programs, enabling population health monitoring and early interventions to reduce costly hospital visits.
Government and public health agencies utilize the platform for remote COVID-19 patient monitoring and quarantine compliance during public health emergencies.
Pricing
Biofourmis does not publicly list pricing information on its website, as its solutions are offered through customized enterprise agreements based on the needs of healthcare organizations, payers, or research partners.
Pricing varies depending on:
Number of patients
Care program (e.g., heart failure, oncology, hospital-at-home)
Required integrations
Device deployment
Support and analytics services
Organizations can request a demo and customized proposal by contacting the Biofourmis sales team directly through the official website.
Strengths
Biofourmis provides continuous, real-time monitoring powered by AI, enabling earlier interventions that improve clinical outcomes and reduce hospital admissions.
The platform supports a wide range of therapeutic areas and is backed by FDA-cleared technology, increasing trust and clinical usability.
Its ability to deliver hospital-grade care at home helps health systems reduce inpatient burden and transition to value-based care models.
Biofourmis’ predictive analytics engine identifies risks proactively, often days before symptoms escalate, allowing clinicians to act early.
The platform is designed with scalability in mind, making it suitable for large health systems, research networks, and payer-led programs.
It improves patient engagement through app-based interactions and education, leading to better compliance and satisfaction.
Integration with EHRs and clinical systems ensures minimal disruption to provider workflows, making adoption smoother.
Drawbacks
The wearable biosensor must be worn consistently to ensure data accuracy, which may be a barrier for patients who are less tech-savvy or non-compliant.
Initial onboarding and setup for providers may require training and operational changes to incorporate remote monitoring into standard care pathways.
As an enterprise-level solution, Biofourmis is not available directly to individual consumers and may not be accessible to all patient populations.
Cost structure and required infrastructure may be a consideration for smaller clinics or providers without strong digital support teams.
Connectivity issues or data gaps may occur in areas with limited internet access, potentially affecting monitoring continuity.
Comparison with Other Tools
Biofourmis competes with remote patient monitoring platforms like Current Health, Philips HealthSuite, and VitalConnect.
Current Health also offers remote monitoring with wearable sensors and supports hospital-at-home models but may not have the same level of predictive analytics as Biofourmis.
Philips HealthSuite offers comprehensive remote monitoring tools, but its systems are often hardware-centric, while Biofourmis excels in software intelligence and AI-driven insights.
VitalConnect provides patch-based monitoring and real-time telemetry but focuses more on inpatient-to-home transitions, whereas Biofourmis supports broader longitudinal care pathways.
What sets Biofourmis apart is its FDA-cleared digital therapeutics, real-time analytics, and machine learning models that go beyond tracking to provide predictive clinical guidance.
Customer Reviews and Testimonials
Biofourmis highlights partnerships and case studies on its website that demonstrate successful implementations in hospitals, health systems, and pharmaceutical research.
Health providers report improved patient adherence, early detection of decompensation, and reduced readmission rates after adopting the platform.
Biofourmis has been recognized in industry publications and by healthcare organizations for its innovation, earning awards from Fast Company and the World Economic Forum.
The company’s solutions have been used in clinical studies with reputable institutions, validating their performance and clinical impact.
Healthcare administrators praise the platform’s scalability, user experience, and the ability to manage large populations with limited clinical resources.
Conclusion
Biofourmis is revolutionizing the delivery of healthcare through its AI-powered remote monitoring and digital therapeutics platform. By combining wearable biosensors, machine learning, and predictive analytics, it enables providers to deliver continuous, personalized care outside the hospital setting.
Whether supporting post-acute recovery, managing chronic conditions, or running decentralized clinical trials, Biofourmis empowers healthcare teams with real-time insights and timely alerts that drive better outcomes.
For hospitals, payers, and biopharma companies seeking to transition to more proactive, patient-centric models of care, Biofourmis offers a clinically validated, scalable, and intelligent solution.
